We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $1.92B
1-Year Est. Return 85.52%
This Fund
S&P 500
This Quarter Est. Return
+1.55%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$1.29B
AUM Growth
-$122M
Cap. Flow
-$104M
Cap. Flow %
-8.05%
Top 10 Hldgs %
31.67%
Holding
282
New
11
Increased
30
Reduced
43
Closed
37

Top Buys

Rank Stock Value
1
BLDR icon
Builders FirstSource
BLDR
+$24.4M
2
HGV icon
Hilton Grand Vacations
HGV
+$15.4M
3
COF icon
Capital One
COF
+$13.8M
4
ERO icon
Ero Copper
ERO
+$10.6M
5
MU icon
Micron Technology
MU
+$8.41M

Top Sells

Rank Stock Value
1
GM icon
General Motors
GM
+$44.2M
2
BURU
NUBURU INC
BURU
+$29.9M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.1M
5
PTOC
Pine Technology Acquisition Corp. Class A Common Stock
PTOC
+$9.77M

Sector Composition

Rank Sector Weight
1 Financials 34.2%
2 Healthcare 21.4%
3 Consumer Discretionary 9.38%
4 Industrials 6.44%
5 Communication Services 5.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMC icon
51
PUT
AMC Entertainment Holdings
AMC
$2.37B
$7.84M 0.61%
112,540
-27,400
-20% -$3.74M
CPAQ
52
DELISTED
Counter Press Acquisition Corporation Class A Ordinary Share
CPAQ
$7.51M 0.58%
745,000
– –
OHAA
53
DELISTED
OPY Acquisition Corp. I Class A Common Stock
OHAA
$7.45M 0.58%
749,899
-101
-0% -$999
MU icon
54
Micron Technology
MU
$1.04T
$7.26M 0.56%
+145,000
New +$8.41M
VMCA
55
DELISTED
Valuence Merger Corp. I Class A Ordinary Shares
VMCA
$7.12M 0.55%
700,000
– –
MRNS
56
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$6.48M 0.5%
975,000
-925,000
-49% -$5.69M
EUCR
57
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$6.01M 0.46%
600,000
– –
NUVB icon
58
Nuvation Bio
NUVB
$2.24B
$5.78M 0.45%
2,580,000
+813,343
+46% +$2.32M
INSW icon
59
International Seaways
INSW
$4.52B
$5.62M 0.43%
160,000
– –
LKFT
60
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.73B
$5.24M 0.4%
122,771
-13,421
-10% -$688K
CBAY
61
DELISTED
Cymabay Therapeutics
CBAY
$5.14M 0.4%
1,470,000
– –
SQZ
62
DELISTED
SQZ Biotechnologies Company
SQZ
$5.12M 0.4%
2,245,000
+87,262
+4% +$262K
TRAQ
63
DELISTED
Trine II Acquisition Corp.
TRAQ
$5.01M 0.39%
499,300
-700
-0.1% -$7.01K
ATRA icon
64
Atara Biotherapeutics
ATRA
$77.5M
$4.91M 0.38%
52,000
-29,800
-36% -$3.35M
NKGN
65
DELISTED
NKGen Biotech, Inc. Common Stock
NKGN
$4.69M 0.36%
481,190
-18,810
-4% -$184K
LEN.B icon
66
Lennar Class B
LEN.B
$20.6B
$4.58M 0.35%
80,899
+4,208
+5% +$256K
CCTS
67
DELISTED
Cactus Acquisition Corp. 1 Limited Class A Ordinary Share
CCTS
$4.52M 0.35%
450,000
– –
PNST
68
DELISTED
Pinstripes Holdings, Inc.
PNST
$4.5M 0.35%
450,000
– –
APMI
69
DELISTED
AxonPrime Infrastructure Acquisition Corporation Class A Common Stock
APMI
$4.28M 0.33%
441,137
-658,862
-60% -$6.39M
ANGI icon
70
Angi Inc
ANGI
$189M
$4.19M 0.32%
142,030
+16,830
+13% +$741K
LIVB
71
DELISTED
LIV Capital Acquisition Corp. II Class A Ordinary Shares
LIVB
$4.07M 0.31%
405,000
– –
PAQC
72
DELISTED
Provident Acquisition Corp. Class A Ordinary Shares
PAQC
$3.98M 0.31%
399,102
-900
-0.2% -$8.92K
GMFI
73
DELISTED
Aetherium Acquisition Corp
GMFI
$3.97M 0.31%
398,200
-1,800
-0.5% -$17.9K
ALDX icon
74
Aldeyra Therapeutics
ALDX
$97.7M
$3.74M 0.29%
700,000
-300,000
-30% -$1.8M
RRAC
75
DELISTED
Rigel Resource Acquisition Corp.
RRAC
$3.53M 0.27%
350,000
– –
1 2
3
4 5

Similar funds

QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $1.91B AUM 24.37% 1-Year Est. Return
MC
Maren Capital Chicago, Illinois $1.91B AUM 17.37% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $1.92B AUM 16.97% 1-Year Est. Return
BOH
Bank of Hawaii Honolulu, Hawaii $1.91B AUM 22.08% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return

683 Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, 683 Capital Management held 282 positions worth $1.29B, down 8.6% from $1.42B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

683 Capital Management withdrew a net $104M in Q3 2022, closing 37 positions and reducing 43 holdings. Its most notable exit was General Motors, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Financials at 34% of assets, up from 34% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, 683 Capital Management opened a new position in Builders FirstSource worth $23M.

  • 683 Capital Management's largest Q3 2022 buy was Builders FirstSource: 390,000 shares worth $23M.
  • 683 Capital Management added most to Capital One in Q3 2022, an estimated $13.8M increase.
  • 683 Capital Management's biggest Q3 2022 reduction was Syndax Pharmaceuticals, cutting an estimated $10.1M.
  • 683 Capital Management fully exited General Motors in Q3 2022, selling an estimated $44.2M.
  • 683 Capital Management's ten largest holdings make up 32% of its $1.29B portfolio in Q3 2022.
  • 683 Capital Management opened 11 new positions and closed 37 in Q3 2022.
  • 683 Capital Management's portfolio value fell 8.6% quarter-over-quarter to $1.29B.

Based on 683 Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.